ストックスクリーナーアプリを入手
22.79
0.39%
-0.09
アフターアワーズ：
22.56
-0.23
-1.01%
前日終値:
$22.88
開ける：
$22.99
24時間の取引高:
47.87M
Relative Volume:
0.99
時価総額：
$134.92B
収益：
$62.46B
当期純損益:
$7.88B
株価収益率:
16.51
EPS:
1.38
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-6.64%
1か月 パフォーマンス:
+0.71%
6か月 パフォーマンス:
-17.01%
1年 パフォーマンス:
-17.93%
1日の値動き範囲:
$22.72
$23.09
1週間の範囲:
$22.72
$24.32
52週間の値動き範囲:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
22.79 | 134.92B | 62.46B | 7.88B | 9.84B | 1.38 |
|
LLY
Lilly Eli Co
|
776.72 | 696.19B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
157.30 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
188.09 | 342.31B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
67.55 | 289.25B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.70 | 224.15B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
The Mindfulness of Medicine Development: How Scientists Are Driving the Next Wave of Medical Innovations - Pfizer
Jim Cramer on Pfizer (PFE): “Trying Big Targets, but New Wins Still Elusive” - Yahoo Finance
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Pfizer (PFE) Awaits FDA Panel Review of Cancer Drug Combination - GuruFocus
Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month - Seeking Alpha
Ex-Dividend Reminder: American Electric Power, Pfizer and Tompkins Financial - Nasdaq
Pharma imports to US surged in March as drugmakers look to avoid tariffs - marketscreener.com
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. - Barron's
Pfizer (PFE) RSV Vaccine Recommendations Under Review - GuruFocus
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aidereport - Seeking Alpha
PFE Stock Price: Pfizer Inc Named Top Dividend Stock as Insider Buying Surges, Yield Hits 7.21% - paginasiete.bo
Pfizer Has Unreasonable Whiff Of The Marlboro Man - Seeking Alpha
Pfizer Named Top Dividend Stock With Insider Buying and 7.21% Yield (PFE) - Nasdaq
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics - TradingView
Here's Why We're Wary Of Buying Pfizer's (NYSE:PFE) For Its Upcoming Dividend - simplywall.st
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend - Yahoo Finance
Recombinant Human Endostatin Market Top PlayersPfizer Inc., - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Sirolimus Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Actiza, Zydus Cadila Healthcare Ltd. - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold? - Zacks Investment Research
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Nasdaq
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strate - GuruFocus
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Pfizer donates $750,000 to tribal health centers in Oklahoma - News On 6
Ibuprofen Drug Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Johnson & Johnson, Bayer AG - openPR.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Fentanyl Drug Market Deep Research Report with Forecast by 2032 | - openPR.com
Pfizer Pulls Plug on Weight-Loss Pill Amid Health Concerns - CEO Today
Pfizer shifts to cost-cutting, new drug research after weight-loss bet fizzles - Crain's New York Business
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Pfizer's Q1 Update May Mark A Bottom In The Stock (NYSE:PFE) - Seeking Alpha
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
1.66%
1.04%
大文字化:
|
ボリューム (24 時間):